{"title":"Inpatient administration of complement inhibitors as rapid-acting therapy for recurrent or refractory myasthenic exacerbation: A case series, review of the literature, and discussion of pathophysiology.","authors":"Julia Greenberg, Muhannad Seyam, Srikanth Muppidi","doi":"10.1016/j.jneuroim.2026.579130","DOIUrl":"https://doi.org/10.1016/j.jneuroim.2026.579130","url":null,"abstract":"<p><strong>Background: </strong>Complement inhibitors are primarily used for symptomatic/refractory but stable myasthenic patients in the outpatient setting, however there is emerging data to suggest that complement inhibitors may be an effective rescue therapy in acute myasthenic exacerbation or crisis.</p><p><strong>Methods: </strong>We present two cases of non-ventilator-dependent patients with refractory or recurrent myasthenic exacerbation in whom eculizumab was used as a rescue therapy, review the literature to date on inpatient use of complement inhibitor therapy for myasthenic crisis/exacerbation, and discuss the pathophysiology underlying rapid clinical response.</p><p><strong>Results: </strong>Both patients had a rapid response to eculizumab with return of ability to speak and swallow within 48 h in one patient and reduction in MG-ADL score of >6 points within 2 weeks in one patient. Both achieved minimal symptom expression (defined as MG-ADL score of 0 or 1) within weeks and had sustained response to outpatient complement inhibitor therapy. Nineteen previously published papers (58 patients) were identified. Many patients had a clinically significant reduction in MG-ADL score or other objective evidence of clinical improvement within days, and had a sustained benefit with continued outpatient therapy.</p><p><strong>Conclusions: </strong>Our findings add to a growing body of literature suggesting that complement inhibition may be a useful, fast-acting therapy for myasthenic exacerbation in the inpatient setting in some cases. This rapid response is likely due to functional complement blockade in patients with complement mediated neuromuscular junction damage as a primary cause of MG exacerbation/crisis.</p>","PeriodicalId":16671,"journal":{"name":"Journal of neuroimmunology","volume":"423 ","pages":"579130"},"PeriodicalIF":3.1,"publicationDate":"2026-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149386904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nan Zhang, Xiaotong Kong, Shihua Yu, Shanshan Peng, Guanghao Xin, Fanfan Xu, Yingying Geng, Guangzhao Zhu, Huixue Zhang, Lihua Wang
{"title":"Urolithin A ameliorates experimental autoimmune myasthenia gravisin association with mitochondrial quality control-related and inflammasome signaling changes.","authors":"Nan Zhang, Xiaotong Kong, Shihua Yu, Shanshan Peng, Guanghao Xin, Fanfan Xu, Yingying Geng, Guangzhao Zhu, Huixue Zhang, Lihua Wang","doi":"10.1016/j.jneuroim.2026.579118","DOIUrl":"https://doi.org/10.1016/j.jneuroim.2026.579118","url":null,"abstract":"<p><strong>Objective: </strong>To characterize peripheral blood mononuclear cell (PBMC) remodeling in myasthenia gravis (MG) at the pathway and transcriptomic level, and to evaluate whether urolithin A (UA) ameliorates experimental autoimmune myasthenia gravis (EAMG) in association with altered mitochondrial quality control-related and NLRP3 inflammasome signaling.</p><p><strong>Methods: </strong>Single-cell RNA-sequencing data from two patients with stable MG and two with MC were analyzed. After quality control, 8414 stable-MG cells and 19,333 MC cells were retained. Cell composition, pathway scores, pseudobulk differential expression, gene-set enrichment, and ligand-receptor interactions were assessed. In parallel, EAMG rats were assigned to control, EAMG, EAMG+UA, or EAMG+UA + chloroquine groups (n = 6/group). Clinical, serological, inflammatory, ultrastructural, mitochondrial quality control-related, and inflammasome-related outcomes were evaluated.</p><p><strong>Results: </strong>MC samples showed heterogeneous immune remodeling, including monocyte enrichment in one patient. Across immune-cell subsets, MC was associated with increased inflammatory, inflammasome/pyroptosis, oxidative-stress, chemotaxis, and lysosome-autophagy programs, whereas mitochondrial quality control-related changes were weaker and cell-type dependent. Exploratory analysis suggested enhanced TNFSF13B-TNFRSF13C interaction scores toward B-cell subsets. In EAMG rats, UA reduced clinical weakness, anti-acetylcholine receptor antibodies, and pro-inflammatory cytokines; improved splenic mitochondrial ultrastructure and PINK1/Parkin-associated mitochondrial quality control marker profiles; and suppressed NLRP3/caspase-1/GSDMD-N signaling. Chloroquine partially reversed these effects.</p><p><strong>Conclusion: </strong>Exploratory scRNA-seq analysis of four patients suggests that MC is associated with pathway-level enrichment of inflammasome/pyroptosis and autophagy/lysosome programs, whereas mitochondrial quality control-related signals were weaker and cell-type-dependent. The EAMG findings support an association between UA treatment, improved mitochondrial quality control-related marker profiles, and reduced inflammasome activation.</p>","PeriodicalId":16671,"journal":{"name":"Journal of neuroimmunology","volume":"423 ","pages":"579118"},"PeriodicalIF":3.1,"publicationDate":"2026-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149379363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Critical advances and translational bottlenecks of gut microbiota-gut-brain axis targeted therapy for neurodegenerative and neurodevelopmental disorders.","authors":"Xinyi Yu, Junrong He, Mei Liu","doi":"10.1016/j.jneuroim.2026.579117","DOIUrl":"https://doi.org/10.1016/j.jneuroim.2026.579117","url":null,"abstract":"<p><p>Neurological diseases have become a major global public health burden. Existing central nervous system-targeted therapies can only alleviate clinical symptoms but fail to halt the progression of neurodegenerative diseases, presenting mechanistic limitations and therapeutic bottlenecks. The gut microbiota participates in the regulation of central nervous system (CNS) homeostasis and neuropathological processes via the microbiota-gut-brain axis (MGBA). Notably, dysbiosis may induce damage to the blood-brain barrier, neurotransmitter dysregulation, and immune imbalance, thereby mediating the onset and progression of various neurological diseases, including Parkinson's disease, Alzheimer's disease (AD), autism spectrum disorder (ASD), and multiple sclerosis (MS). This article provides a systematic review of the core mechanisms by which the gut microbiome regulates neurological diseases, including inflammation regulation, oxidative stress responses, and neuroendocrine remodeling mediated by microbial metabolites. It also comprehensively summarizes the research progress, application advantages, and existing limitations of novel gut-targeted interventions, such as probiotics, prebiotics, fecal microbiota transplantation (FMT), dietary interventions, and live biological therapies. At the same time, the article critically examines key bottlenecks prevalent in the field: the causal relationship between the microbiota and disease remains unclear; there is a significant translational gap between animal and human studies; there is a lack of unified standards for multi-omics analysis systems; and interference from confounding factors such as age, diet, and medications is significant. Existing research indicates that gut microbiota interventions complement traditional symptomatic treatments and hold promising prospects for early disease intervention and adjunctive therapy for refractory patients. Future efforts should integrate multi-omics and artificial intelligence technologies to decipher the causal networks governing gut-central nervous system regulation, establish standardized research frameworks, advance the clinical translation of precision gut microbiota therapies, and provide new approaches for the comprehensive prevention, control, and personalized treatment of neurological disorders.</p>","PeriodicalId":16671,"journal":{"name":"Journal of neuroimmunology","volume":"423 ","pages":"579117"},"PeriodicalIF":3.1,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149379362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Viviana Cristillo, Tommaso Merati, Chiara Tolassi, Alessandro Rondina, Valentina Bettonagli, Alice Galli, Irene Volonghi, Marta Bianchi, Davide Arici, Chiara Trasciatti, Irene Girotto, Roberto Gasparotti, Andrea Pilotto, Alessandro Padovani
{"title":"Integrated NULISA-based CSF neuroimmune profiling identifies microglial-axonal injury signatures and their clinical and MRI associations in new-onset Multiple Sclerosis.","authors":"Viviana Cristillo, Tommaso Merati, Chiara Tolassi, Alessandro Rondina, Valentina Bettonagli, Alice Galli, Irene Volonghi, Marta Bianchi, Davide Arici, Chiara Trasciatti, Irene Girotto, Roberto Gasparotti, Andrea Pilotto, Alessandro Padovani","doi":"10.1016/j.jneuroim.2026.579113","DOIUrl":"https://doi.org/10.1016/j.jneuroim.2026.579113","url":null,"abstract":"<p><strong>Background: </strong>Multiple sclerosis (MS) is characterized by inflammatory demyelination, neuroaxonal injury and progressive neurodegeneration. The biological processes driving the disease are already active at clinical onset, yet comprehensive characterization of different molecular pathways at diagnosis remains limited.</p><p><strong>Objective: </strong>To integrate high-sensitivity NULISA-based CSF biomarker profiling with neurological impairment at clinical presentation, MRI lesion burden, and microstructural diffusion metrics in normal-appearing white matter (NAWM) in treatment-naïve newly diagnosed MS patients.</p><p><strong>Methods: </strong>CSF samples were collected from 70 treatment-naïve newly diagnosed MS patients and 11 age- and sex-matched non-inflammatory neurological controls (NINCs). A CNS Disease Panel of 120 CSF biomarkers was quantified using ultra-sensitive NULISA technology. Differential expression analysis across the NULISA panel was controlled using the Benjamini-Hochberg false discovery rate (FDR). Secondary multivariable regression and partial-correlation analyses evaluated associations with baseline EDSS, short-term change in EDSS following high-dose corticosteroid treatment, white matter lesion volume, and NAWM ADC measures. These secondary analyses were considered exploratory.</p><p><strong>Results: </strong>Seven biomarkers were significantly increased in MS compared with controls after FDR correction: REST, IL-16, CHI3L1, NfL, ICAM-1, TREM2, and CHIT1. Correlation analysis demonstrated clustering among markers of glial and innate immune activation (CHI3L1, TREM2, CHIT1) and moderate associations between NfL and glial markers. REST was strongly correlated with IL16, suggesting early transcriptional and immune pathway interplay. In multivariable models, higher levels of glial activation markers were associated with neurological impairment at clinical presentation in exploratory multivariable analyses. CSF NfL levels correlated with white matter lesion burden and were significantly associated with diffusion abnormalities in NAWM, particularly in the genu of the corpus callosum, cingulum, and anterior corona radiata, These exploratory associations link CSF NfL with both focal lesion burden and selected NAWM microstructural abnormalities.</p><p><strong>Discussion: </strong>High-sensitivity NULISA profiling identified co-occurring inflammatory, glial, and neuroaxonal injury signals at MS onset and exploratory associations with clinical and MRI measures, supporting the feasibility of this approach for characterizing early MS biology.</p><p><strong>Conclusions: </strong>NULISA-based CSF profiling captures complementary neuroimmune and neuroaxonal injury signals in treatment-naïve MS at diagnosis. Prospective studies are needed to determine their longitudinal clinical relevance.</p>","PeriodicalId":16671,"journal":{"name":"Journal of neuroimmunology","volume":"423 ","pages":"579113"},"PeriodicalIF":3.1,"publicationDate":"2026-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149371025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Immuno-deficient features of thymoma-associated myasthenia gravis patients with hypogammaglobulinemia: A condition comparable to Good's syndrome","authors":"Saki Nakashima , Kaori Sakuishi , Manato Hara , Reiko Kawasaki , Toshiyuki Kakumoto , Hiroyuki Ishiura , Tatsushi Toda","doi":"10.1016/j.jneuroim.2026.578885","DOIUrl":"10.1016/j.jneuroim.2026.578885","url":null,"abstract":"<div><div>Good's syndrome (GS) is a rare immunodeficiency disorder associated with thymoma, characterized by hypogammaglobulinemia and recurrent infections; however, its clinical significance in thymoma-associated myasthenia gravis (TAMG) remains unclear. We retrospectively reviewed 30 patients with TAMG admitted to our center between January 2010 and March 2022. We defined GS-like immunodeficiency as serum IgG below the institutional cutoff of 861 mg/dL and a history of two or more infections requiring antimicrobial treatment; 11 patients (36.7%) met this definition. Compared with the remaining patients, the GS-like group had higher incidences of malignancy (45.5% vs. 5.3%, <em>p</em> = 0.016) and autoimmune diseases other than MG (36.4% vs. 5.3%, <em>p</em> = 0.047), lower peripheral lymphocyte counts (median 1100/μL vs. 2200/μL, <em>p</em> = 0.0051), and more frequent airflow obstruction defined by one second to forced vital capacity ratio of less than 70% (60.0% vs. 5.3%, <em>p</em> = 0.0026). Five deaths occurred in the GS-like group, and none in the other; median survival from the first antimicrobial-treated infection was 5.0 years. These findings imply that TAMG patients with GS-like immunodeficiency have a worse prognosis, underscoring the need for close monitoring and timely adjustments of MG management. (189 words).</div></div>","PeriodicalId":16671,"journal":{"name":"Journal of neuroimmunology","volume":"414 ","pages":"Article 578885"},"PeriodicalIF":2.5,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146165826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Possible risk of rheumatoid arthritis treated with methotrexate to the central nervous system relapse of diffuse large B-cell lymphoma","authors":"Rie Tabata , Hiroko Uesugi , Chiharu Tabata","doi":"10.1016/j.jneuroim.2026.578877","DOIUrl":"10.1016/j.jneuroim.2026.578877","url":null,"abstract":"<div><h3>Purpose</h3><div>Relapse in the CNS is uncommon but often a fatal event in the patients with diffuse large B-cell lymphoma. An important management strategy consists of identifying patients in the high-risk group for CNS relapse and choosing those who will benefit from CNS prophylaxis. To evaluate rheumatoid arthritis as an additional risk factor for CNS relapse, we retrospectively examined the patients with DLBCL.</div></div><div><h3>Methods</h3><div>We examined 85 patients with diffuse large B-cell lymphoma, admitted to the hospital between June 2016 and May 2021 and followed up for at least three years, and investigate the background of nine patients with CNS relapse. CNS relapse was diagnosed by imaging, clinical, and histological or cytological findings. Also, we evaluated patients with a history of rheumatoid arthritis in these 85 patients. Statistical analysis was performed using Fisher's exact test (Statcel-the Useful Addin Forms on Excel-4th ed.)</div></div><div><h3>Results</h3><div>In the present study, we showed that nine of 85 patients (10.6%) developed CNS relapse. Three of nine cases with CNS relapse had none of the previously reported risks, but received low-dose methotrexate for rheumatoid arthritis. We observed a high proportion of CNS relapse among patients with diffuse large B-cell lymphoma and concomitant rheumatoid arthritis The association between CNS relapse and concomitant rheumatoid arthritis in diffuse large B-cell lymphoma was statistically significant. (CNS relapse / history of RA: +/+ 3, +/− 6, −/+ 5, −/− 71; <em>p</em> = 0.036), using Fisher's exact test.</div></div><div><h3>Conclusions</h3><div>Here we demonstrated a possible risk of rheumatoid arthritis for CNS relapse in diffuse large B-cell lymphoma. High-dose intravenous methotrexate has been increasingly used as a CNS prophylaxis instead of intrathecal methotrexate injection alone in patients with high-risk diffuse large B-cell lymphoma. However, our findings suggest that MTX re-administration in patients with rheumatoid arthritis with diffuse large B-cell lymphoma and high CNS relapse risk warrants particular caution.</div><div>Clinicians should be aware of the possible risks in these patients, and careful consideration is needed.</div></div>","PeriodicalId":16671,"journal":{"name":"Journal of neuroimmunology","volume":"414 ","pages":"Article 578877"},"PeriodicalIF":2.5,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146125374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Linqi Liu , Dan Lu , Wenjun Que , Rui Fan , Wei Zheng , Yaoqi Gan , Fei Xiao
{"title":"Docosahexaenoic acid supplementation aggravates myasthenia gravis through immune dysregulation","authors":"Linqi Liu , Dan Lu , Wenjun Que , Rui Fan , Wei Zheng , Yaoqi Gan , Fei Xiao","doi":"10.1016/j.jneuroim.2026.578889","DOIUrl":"10.1016/j.jneuroim.2026.578889","url":null,"abstract":"<div><div>Myasthenia gravis (MG) is an autoimmune disorder characterized by the disruption of immune cell homeostasis and inflammatory processes. However, the impact of metabolic abnormalities on immune regulation in MG has not been well defined. The objective of this study was to identify serum metabolites causally linked to MG and to explore their role in the onset and progression of the disease. This will provide a theoretical foundation for targeted clinical interventions and therapeutic strategies. To establish the causal relationship between serum metabolites and MG, we employed Mendelian randomization. Furthermore, we conducted dietary interventions with docosahexaenoic acid (DHA) to observe its effects on the disease progression and immune cell subpopulations in experimental autoimmune myasthenia gravis (EAMG) rats. We also performed metabolomic and transcriptomic analyses of regulatory T cells (Treg) during MG progression. Our findings suggest that dysregulated lipid metabolism, particularly elevated DHA levels, is a significant risk factor for MG, influencing various markers associated with Treg cells in both MG patients and in EAMG models. The addition of 1% DHA to the diet exacerbated the severity of EAMG, enhanced B cell immune responses, and promoted antibody production. However, it also led to an increase in the proportion of Treg cells. Further in vitro experiments confirmed that DHA accumulation in Treg cells enhances their proliferation but impairs their inhibitory function, partially through the PI3K-Akt signaling pathway. These results imply that modulating lipid metabolism, especially through the PI3K-Akt pathway in Treg cells, could be critical in controlling MG.</div></div>","PeriodicalId":16671,"journal":{"name":"Journal of neuroimmunology","volume":"414 ","pages":"Article 578889"},"PeriodicalIF":2.5,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146172462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Longitudinal MuSK antibody levels may correlate with disease severity in MuSK myasthenia gravis","authors":"Manato Yasuda , Akiyuki Uzawa , Etsuko Ogaya , Hideo Handa , Kentaro Kurumada , Kyosuke Takasaka , Hiroyuki Akamine , Yukiko Ozawa , Satoshi Kuwabara","doi":"10.1016/j.jneuroim.2026.578876","DOIUrl":"10.1016/j.jneuroim.2026.578876","url":null,"abstract":"<div><h3>Background</h3><div>In muscle-specific kinase antibody-positive myasthenia gravis (MuSK-MG), the clinical utility of MuSK antibody levels as a biomarker for disease severity is debated, with conflicting reports on its correlation with clinical status. This study aimed to clarify this association by applying a rigorous statistical model to a longitudinal dataset followed from an immunotherapy-naïve state.</div></div><div><h3>Methods</h3><div>We conducted a retrospective longitudinal study on 6 patients with MuSK-MG tracked from their treatment-naïve baseline. The primary analysis used 103 data points where MuSK antibody levels and MG activities of daily living (MG-ADL) scores were available. A secondary analysis used the subset of 81 data points where total immunoglobulin G (IgG) levels were also concurrently measured. Generalized linear mixed-effects models (GLMM) were used to assess the intrapatient correlation, adjusting for interpatient variability by including a random intercept for each subject.</div></div><div><h3>Results</h3><div>First, the GLMM analysis of 103 data points revealed a strong positive intrapatient correlation between MuSK antibody levels and MG-ADL scores (<em>P</em> < 0.001). Second, in the subset analysis (<em>n</em> = 81), MuSK antibody levels remained positively and specifically correlated with MG-ADL scores (<em>P</em> = 0.002), whereas total IgG levels showed no independent correlation (<em>P</em> = 0.61) when included in the same model.</div></div><div><h3>Conclusions</h3><div>MuSK antibody level, unlike total IgG, is a specific and valuable biomarker for monitoring intrapatient disease activity and therapeutic response. These findings strongly support the utility of serial MuSK antibody monitoring within individual patients.</div></div>","PeriodicalId":16671,"journal":{"name":"Journal of neuroimmunology","volume":"414 ","pages":"Article 578876"},"PeriodicalIF":2.5,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146137488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Xiaofang Liu , Xiaohong Jiang , Zijia Chen , Xiaona Xue , Sumei Wang , Lvping Lin
{"title":"Effect of pharmacological intervention and pathogenesis discussion about rats with tic disorders","authors":"Xiaofang Liu , Xiaohong Jiang , Zijia Chen , Xiaona Xue , Sumei Wang , Lvping Lin","doi":"10.1016/j.jneuroim.2026.578878","DOIUrl":"10.1016/j.jneuroim.2026.578878","url":null,"abstract":"<div><div>To investigate the pathogenesis of Tic disorders (TD), particularly their relationship with central nervous system inflammation, we conducted an animal experiment. A TD model was established for rats, and their behavior and immune cytokines and receptor in the striatum were compared between a diseased group and healthy control group of rats. After receiving effective drug interventions (the traditional Chinese medicine Jian-Pi-Zhi-Dong decoction (JPZDD) and the Western medicine Tiapride), we observed changes in behavior and immune cytokine and receptor expression in the striatum and analyzed the association between central nervous system inflammation and TD. The results are as follows: (1) Successful modeling: Compared to normal rats, TD diseased rats exhibited increased spontaneous activity, stereotypical exercise, and elevated expression of inflammatory cytokines and receptor in the striatum. (2) Effective pharmacological intervention: Tiapride and JPZDD reduced spontaneous activity, stereotypical exercise, and the expression of inflammatory cytokines and receptor in rats with TD. (3) The number of spontaneous activities and stereotypical exercise scores was positively correlated with central nervous system inflammation. The expression of Toll-like receptor 4 (TLR4), interleukin-6 (IL-6), interleukin-8 (IL-8), and tumor necrosis factor-alpha (TNF-α) in the striatum of the diseased group rats were significantly greater than those in the striatum of the normal group rats. Effective pharmacological intervention reduced the expression of inflammatory cytokine and receptor in the striatum, bringing them to expression similar to those in normal rats. Based on these results, we conclude that TD is associated with central nervous system inflammation and that the severity of TD is positively correlated with the severity of central nervous system inflammation. We hypothesize that the pathogenesis of TD may involve elevated TLR4, which triggers overactivation of microglia in the brain resulting in the release of excessive IL-6, IL-8, and TNF-α. This process damages neurons and leads to tic symptoms in patients.</div></div>","PeriodicalId":16671,"journal":{"name":"Journal of neuroimmunology","volume":"414 ","pages":"Article 578878"},"PeriodicalIF":2.5,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146172391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
David F. Alfonso-Cedeño , Lorena Medina-Lozano , Paula V. Gaete , Patricia Quintero-Cusguen
{"title":"Bilateral optic neuritis preceding a Baló concentric sclerosis lesion: A case report and literature review","authors":"David F. Alfonso-Cedeño , Lorena Medina-Lozano , Paula V. Gaete , Patricia Quintero-Cusguen","doi":"10.1016/j.jneuroim.2026.578874","DOIUrl":"10.1016/j.jneuroim.2026.578874","url":null,"abstract":"<div><div>Baló's concentric sclerosis (BCS) is a rare inflammatory demyelinating disorder characterised by a pathologic appearance of concentric layers of demyelinated and partially myelinated fibres, with a distinctive “onion bulb” pattern on magnetic resonance imaging (MRI). Due to its rarity and overlapping features with multiple sclerosis and neuromyelitis optica spectrum disorder (NMOSD), diagnosis is challenging. We report the case of a 60-year-old male with hypertension who presented with acute bilateral painless vision loss, absent pupillary light reflex, and marked photophobia. Initial brain and orbital MRI were normal, but cervical spine MRI revealed a demyelinating lesion from C5 to C6. Cerebrospinal fluid (CSF) showed type 1 oligoclonal bands and negative anti-aquaporin 4 and anti-myelin oligodendrocyte glycoprotein antibodies. The patient was initially diagnosed with seronegative NMOSD and treated with intravenous methylprednisolone without improvement. One month later, he developed spastic dysarthria and dysphagia; brain MRI showed a right pre-Rolandic lesion with concentric rings associated with the previously reported demyelinated lesion in the cervical spinal cord and other demyelinated lesions in the brainstem. CSF analysis during relapse revealed hyperproteinorrhachia and mild hypoglycorrhachia without infectious or autoimmune markers. Plasmapheresis led to the resolution of bulbar symptoms. Given clinical relapse and lesion progression, rituximab therapy was initiated, achieving clinical stability. This case illustrates the diagnostic complexity of BCS, the importance of integrating imaging and immunological findings, and the potential role of B-cell–depleting therapy in preventing new relapses.</div></div>","PeriodicalId":16671,"journal":{"name":"Journal of neuroimmunology","volume":"413 ","pages":"Article 578874"},"PeriodicalIF":2.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146079053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}